Doherty Catherine T. sold $5.5M of DGX
Doherty Catherine T. (Executive Vice President) sold 22,105 shares of QUEST DIAGNOSTICS INC (DGX) at an average of $248.02 ($245.45–$251.24, $5.48M total) across 7 trades on 2026-11-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the insider's ownership stake, which may be interpreted by investors as a bearish signal, though the pre‑arranged nature tempers the impact.
Market read
The filing provides fresh, material information about insider holdings, offering a modest trading cue for DGX.
What to watch
Potential upcoming earnings or strategic moves not disclosed may be the real driver of the sale.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates the sale was pre‑scheduled, reducing speculation about motive.
Ticker impact
Executive Vice President Catherine Doherty sold 22,105 shares for $5.48M via a 10b5‑1 plan, reducing her stake to 71,949 shares.
likely pressure as the market prices in the insider sell
A $5.5M sale by a top executive is material for a mid‑cap stock and can influence short‑term sentiment, though the transaction was pre‑arranged.
Market effects
Minimal impact on the broader healthcare diagnostics sector; insider sales are company‑specific.
Limited to U.S. markets where DGX trades.
Low global relevance.
Counterpoint
The sale could be purely procedural under a 10b5‑1 plan, not reflecting negative outlook.
Key entities
- companyQuest Diagnostics Inc.
U.S. provider of diagnostic testing services, ticker DGX.
- executiveCatherine T. Doherty
Executive Vice President of Quest Diagnostics, reporting the insider sale.


